The activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) is characterized by the chronic activation of signaling initiated by immunoglobulin-µ (IgM). By analyzing DNA copy profiles of 1,000 DLBCLs, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. We show that these alterations target the TCF4 (E2-2) transcription factor, and that over-expression of TCF4 leads to its occupancy on immunoglobulin gene enhancers and increased expression of IgM at the transcript and protein level. The TCF4 gene is one of the top BRD4-regulated genes in DLBCL. Using a BET proteolysis-targeting chimera (PROTAC) we show that TCF4 and IgM expression can be extinguished, and ABC-like DLBCL cells can be killed in vitro and in vivo. This highlights a novel genetic mechanism for promoting immunoglobulin signaling in ABC-like DLBCL and provides a functional rationale for the use of BET inhibitors in this disease.
INTRODUCTION 1
Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma and is curable in 2 ~60% of patients using a combination chemo-immunotherapy regimen, R-CHOP 1,2 . However, 3 those that are refractory to, or relapse following, first-line therapy have a dismal outcome 3 . 4
Chimeric antigen receptor (CAR)-T cells are likely to change the landscape of outcomes in 5 relapsed/refractory patients, but a large number of patients are not eligible for CAR-T therapy and 6 ~50% of those that received CAR-T progress within 12 months 4 . Novel rationally-targeted 7 therapeutic strategies are therefore needed for DLBCL. been shown to promote this signaling, including mutations of the CD79A, CD79B, CARD11, and 20
MYD88 genes [8] [9] [10] [11] . However, these mutations only account for approximately two thirds of ABC-21 like DLBCL cases 12 , suggesting that other significant genetic drivers remain to be defined. 22
23
A common mechanism for tumorigenesis is the gain or loss of DNA encoding oncogenes or tumor 24 suppressor genes, respectively. These copy number alterations (CNAs) perturb a higher fraction 25 of the cancer genome than somatic nucleotide variants (SNVs) and small insertion/deletions 26 (InDels) and are critically important to cancer etiology 13 . Here, we have integrated multiple 27 datasets, including DNA copy number profiles of 1,000 DLBCLs, and identified DNA copy number 28 gain of the E2 transcription factor TCF4 as the most frequent genetic alteration in ABC-like 29 DLBCL. We show that TCF4 is capable of driving IgM expression and is amenable to therapeutic 30 targeting through BET inhibition. These data therefore highlight a novel genetic basis for ABC-31 like DLBCL with potential implications for future clinical studies. 32
33

RESULTS
35
DNA copy number gains of chromosome 18 are the most frequent genetic alteration in DLBCL. 36 In order to identify significant CNAs in DLBCL, we interrogated the genomic profiles of 1,000 37 DLBCLs using the GISTIC2 algorithm 14 . These included high-resolution SNP microarrays from 38 860 previously published cases, in addition to next generation sequencing (NGS)-derived profiles 39 from our own cohort of 140 cases (Table S1 -2). Our analysis revealed 20 significant DNA copy 40 number gains and 21 significant DNA copy number losses (false discovery rate [FDR] <0.1; Fig.  41 1A and Table S3 ). Using a subset of 448 cases for which COO subtype data was available, we 42 identified 9 DNA copy number alterations that were significantly more frequent in ABC-like DLBCL 43 and 11 that were significantly more frequent in GCB-DLBCL (Fisher Q-value<0.1; Fig. 1B and S1; 44 Table S4 ). The most frequent genetic alteration in ABC-like DLBCL was gain of 18q21.2, which 45 was observed in 44% of tumors. In line with the association with ABC-like DLBCL, 18q21.2 gains 46 were associated with significantly reduced overall survival in both CHOP and R-CHOP treated 47 patients ( Fig 1C-D) . Using 199 tumors with matched COO subtype, DNA copy number data and 48 mutation status for 40 genes, we observed that the frequency of 18q21 gains (23.1% of all tumors; 49 40.7% of ABC-like tumors) was higher than other ABC-like DLBCL-associated somatic mutations 50 including MYD88 mutation (16.6% of all tumors; 33.3% of ABC-like tumors), CD79B mutation 51 (7.5% of all tumors; 18.5% of ABC-like tumors) and other ABC-associated genes ( Fig 1E, S2 and 52 Table S5 ). Because multiple genetic alterations are associated with ABC-like DLBCL, we 53 employed the REVEALER algorithm 15 to identify the set of genetic alterations that best explained 54 the ABC-like DLBCL signature. Using a set of 87 DNA copy number alterations and recurrently 55 mutated genes as the feature set and MYD88 mutations as the seed feature, REVEALER 56 identified an additional 4 genetic alterations including 18q21.2 gain as those best associating with 57 the ABC-like signature ( Fig. 1F ). Gains of 18q21 are therefore the most frequent genetic feature 58 of ABC-like DLBCL and are predicted to contribute to this molecular phenotype. 59
60
The TCF4 (E2-2) transcription factor is the target of 18q21 gains in ABC-like DLBCL 61
Gains of 18q have been previously attributed to the BCL2 oncogene 16,17 . However, our analysis 62 of this large cohort provided the resolution to identify two significant peaks of DNA copy gain on 63 chromosome 18; 18q21.2 (16 genes, Q=4.8x10 -14 ) and 18q22.1 (70 genes, Q=1.1x10 -7 ; Table  64 S3). We further integrated GEP data from 249 tumors to identify the likely targets of these lesions 65 by testing for the increase in expression of genes within the most significant peaks of DNA copy 66 gain. This highlighted TCF4 and BCL2 as likely targets of the 18q21.2 and 18q22.1 gains, 67 respectively ( Fig. 2A ; Table S6 ). Notably, most 18q copy number alterations incorporated both of these genes (Fig 2A-C ). Only 7.3% or 1.0% of ABC-like DLBCLs have copy number alterations 69 targeting TCF4 or BCL2 alone, respectively ( Fig. 2B-C ). In addition, we observed that TCF4 was 70 more highly expressed in ABC-like DLBCL compared to GCB-like DLBCL generally, but was 71 further increased by DNA copy gain ( Fig 2D) . In line with this, ABC-like DLBCL cell lines 72 expressed TCF4 protein irrespective of DNA copy number, but these levels were significantly 73 increased by DNA copy gain ( Fig 2E) . 74
75
The TCF4 gene encodes an E2 family transcription factor, E2-2. Mutations of another E2 76 transcription factor, TCF3, and its negative regulators ID2 and ID3 are frequent in Burkitt's 77 lymphoma (BL) and promote immunoglobulin signaling 18, 19 . We therefore interrogated the 78 mutation status of these genes and TCF4 copy gains in our cohort of 140 DLBCLs and a prior 79 cohort of 108 BLs that were sequenced and analyzed with the same approach 20 . We did not 80 observe recurrent mutations of TCF4 or ID2 in this BL cohort, and mutations of TCF3 and ID3 81 were infrequent in DLBCL (data not shown). However, in BL, gains of TCF4 were present at the 82 same frequency as TCF3 mutations (18%). Furthermore, TCF4 gains were significantly mutually-83 exclusive from TCF3 and ID3 mutations (Fisher P=0.019; Fig. 2F ), suggesting that TCF4 gains 84 may serve a similar function as TCF3/ID3 mutations in promoting immunoglobulin signaling. 85
These data therefore show that the TCF4 gene is highly expressed in ABC-like DLBCL, with 86 expression further promoted by frequent 18q21.2 DNA copy gains, and implicates TCF4 in 87 immunoglobulin signaling. 88 89 TCF4 regulates IgM and MYC expression in ABC-like DLBCL 90
To identify potential target genes of TCF4, we performed differential gene expression analysis of 91 primary DLBCL tumors with TCF4 DNA copy gain (n=51) compared to those without (n=59). This 92 analysis was limited to ABC-like tumors so as to eliminate the confounding effect of genes that 93 differ in expression between COO subtypes. A total of 355 genes (472 probe-sets) and 87 genes 94 (107 probe-sets) were found to be expressed at significantly higher or lower levels in tumors with 95 TCF4 gain, respectively (Q<0.1, fold-change≥1.2; Fig 3A; Table S7 ). We performed ChIP-seq of 96 ABC-like DLBCL cell lines, SUDHL2 and TMD8, with tetracycline-inducible Myc-DDK-tagged 97 TCF4 in order to define whether these genes were direct transcriptional targets of TCF4 ( Fig 3A) . 98 Importantly, TCF4 was expressed at a level comparable to that in the U2932 cell line with TCF4 99 copy gain ( Fig. S3 ). Using the intersection of significant peaks from both cell lines, we identified 100 TCF4 binding proximal to 180/355 genes with increased expression and 46/87 genes with 101 decreased expression in tumors with TCF4 copy gain ( Fig. 3A-B ; Table S8 ). These peaks showed a highly significant enrichment of motifs containing E-box consensus sequences (CANNTG; Fig.  103 S4), and many of the same regions are also bound by TCF4 in plasmacytoid dendritic cell 104 neoplasms 21 (Fig. S4 ), providing strong evidence that we detected on-target binding. Among the 105 most significant ChIP-seq peaks were those within the immunoglobulin heavy chain locus ( Fig The TCF4 gene is one of the most highly BRD4-loaded genes in DLBCL, including in ABC-like 118 DLBCL cell lines with TCF4 copy gain ( Fig. S6 ). We therefore evaluated small molecule BET 119 inhibitors and a BET protein degrader, ARV771, as a potential avenue for reducing TCF4 120 expression in ABC-like DLBCL cell lines with high-copy number of TCF4. The small molecule BET 121 inhibitors, JQ1 and OTX015, resulted in an up-regulation of BRD4 that was not observed with 122 ARV771 due to its role as a sub-stoichiometric BRD4 degrader ( Fig 4A and S7 ). This was 123 associated with a greater efficacy of ARV771 in reducing the BRD4 target genes, MYC and TCF4 124 ( Fig 4A) , and the ability of ARV771 to induce apoptosis of these cell lines ( Fig 4B) . However, as 125 MYC is also a target of TCF4, the down-regulation of MYC is likely partially mediated through 126
TCF4. 127 128
Reductions of TCF4 by ARV771 treatment were accompanied by reduced expression of the TCF4 129 target genes. This included significant reductions of IgM at the transcript and protein level ( Fig.  130 4C-D and Table S9 ). ARV771 treatment led to significant down-regulation of the set of genes that 131 were identified as being increased in association with TCF4 DNA copy number gain in primary that express high levels of TCF4, we observed that ARV771 was able to significantly reduce tumor 135 growth. At the end of treatment, tumors were significantly smaller in ARV771-treated mice and this led to a significant prolongation of survival in these mice (Log Rank P-value < 0.05). Together 137 these data demonstrate a clear functional rationale for BET inhibition in ABC-like DLBCL, and 138
show that ARV771 is effective at eliminating TCF4 and its target genes and treating ABC-like 139
The ABC-like subtype is one of two major molecular subtypes of DLBCL that is recognized by the 143 WHO classification 22 . These tumors are driven by chronic active B-cell receptor signaling that 144 emanates from autoreactive IgM that is localized to the cell surface and intracellular lysosomes 8,23-145 25 . Mutations in CD79B and MYD88 deregulate this signaling through the reduction of LYN-146 mediated negative feedback and by activation of IRAK signaling, respectively 8,10 . However, recent 147 murine studies have shown that MYD88 mutation alone drove a phenotype that was reminiscent 148 of peripheral tolerance, and this was only relieved by the combination of MYD88 and CD79B 149 mutations together, or by increased expression of surface IgM 26 . The ABC-like phenotype is 150 therefore the result of cumulative epistatic genetic alterations, rather than a single dominant driver 151 mutation. In further support of this notion, recent genomic studies have defined co-associated 152 sets of genetic alterations that co-segregate with unique genetic subsets of ABC-like DLBCL 27 . 153
The "cluster 5" subset of ABC-like DLBCL included frequent MYD88 and CD79B mutations, but 154 the most frequent genetic alteration in this subtype was DNA copy number gain of 18q 27 . 155
156
We identified the TCF4 (aka E2-2) gene as the most significant target of 18q DNA copy number 157 gains in DLBCL. The TCF4 gene (aka E2-2) is closely related to TCF3 (aka E2A), with both 158 encoding helix-loop-helix transcription factors that form dimers and recognize E-box consensus 159 sequences (CANNTG) 28 . Murine conditional knock-out studies showed that TCF3 and TCF4 are 160 critical regulators of germinal center B-cell and plasma cell development, in part due to their role 161 in activating immunoglobulin heavy-and light-chain enhancer elements 29,30 . The ID2 and ID3 162 proteins bind to and inhibit the activity of TCF3 and TCF4 by preventing their dimerization and 163 DNA binding 28 . The TCF3 and ID3 genes are recurrently mutated in another form of B-cell 164 lymphoma, Burkitt Lymphoma, with the mutations residing in the interface between TCF3 and ID3 165 and preventing their interaction 18, 19 . Mutations in ID3 are approximately twice as frequent as 166 mutations of TCF3, and presumably also reduce the interaction between ID3 and TCF4 167 considering the high degree of homology between these two proteins. We observed that TCF4 168 DNA copy number gains are also frequent in Burkitt lymphoma, and that they mutually exclude 169 TCF3 and ID3 mutations, providing further evidence for the importance of TCF3/TCF4 deregulation in this disease. In contrast to Burkitt lymphoma, TCF3 and ID3 mutations are rare in 171 ABC-like DLBCL, but TCF4 DNA copy number gains are present at more than twice the 172 frequency. In line with the murine studies, we observed a marked up-regulation of IgM transcript 173 expression in primary tumors with TCF4 DNA copy number gain. We also identified binding sites 174 for TCF4 in the immunoglobulin heavy chain locus and showed that induced expression of TCF4 175 was sufficient for increasing the expression of IgM at the transcript and protein level. Together, 176 this provides strong evidence for a functional role of TCF4 in promoting IgM expression in ABC-177 like DLBCL. This is particularly important in this disease, because >90% of ABC-like DLBCL cases 178 express IgM and the disease etiology centers on pathogenic signaling downstream of this 179 receptor 7,8 . Notably, TCF4 was more highly expressed in ABC-like DLBCL compared to GCB-like 180 DLBCL generally, even in cases without DNA copy number gain of the locus. This suggests that 181 this axis may be active in all ABC-like DLBCLs, and further enhanced in the ~40% that harbor 182 18q DNA copy number gains. This is akin to the role of EZH2 in GCB-like DLBCL, which promotes 183 the survival and proliferation of all germinal center B-cells but has enhanced activity in the context 184 of hypomorphic somatic mutations 31,32 . We therefore hypothesize that TCF4 may participate in a 185 critical functional axis of immunoglobulin regulation in all ABC-like DLBCL. include key transcription factors such as BCL6, PAX5 and IRF4 35 . We have highlighted TCF4 as 190 another prominent target of BRD4 in DLBCL, as has been previously described in plasmacytoid 191 dendritic cell neoplasms 21 . Due to the difficulty in directly drugging transcription factors, BET 192 inhibition therefore represents a logical avenue for reducing TCF4 expression in ABC-like DLBCL. 193
Notably, cell line studies have shown that the small molecule BET inhibitor OTX015 induces 194 apoptosis in ABC-like DLBCL cell lines, as compared to a predominantly cytostatic effect in GCB-195 like DLBCL cell lines 36 . However, small molecule inhibitors have also been shown to result in the 196 up-regulation of BRD4 expression 37 . We therefore evaluated a novel BET protein PROTAC, ARV-197 771, which combines a BET-targeting warhead from OTX015 with a moiety that recruits the VHL 198 ubiquitin ligase 37 . Because the PROTAC is not degraded, this results in sub-stoichiometric 199 proteolysis of BET proteins, including BRD4. We found that ARV-771 was able to inhibit the 200 expression of TCF4 at 10-fold lower concentrations than small molecule BET inhibitors. The 201 inhibition of TCF4 expression in ABC-like DLBCL cell lines with high TCF4 copy number was 202 accompanied by the coordinate down-regulation of genes that were highly expressed in primary 203 tumors with TCF4 DNA copy gain, suggesting that a subset of the broad transcriptional changes associated with BRD4 degradation were the consequence of reduced TCF4. This was also 205 associated with the induction of apoptosis at low nanomolar doses of ARV-771, significant 206 reduction of tumor growth in vivo, and a significant prolongation in the life of tumor-bearing 207 animals. Together, this highlights TCF4 DNA copy gains as a functional rationale for BET 208 inhibition in ABC-like DLBCL and shows that the BET PROTAC ARV-771 has significant activity 209 in this context. The over-expression of BCL2 has been described as a resistance mechanism for 210 BET inhibitors 38 . We observed that the majority of 18q DNA copy number gains in DLBCL 211 encompass both the TCF4 and the BCL2 gene, and we therefore posit that the promising activity Publicly available data for single nucleotide polymorphism microarrays and array comparative 229 genome hybridization platforms with >200,000 markers were downloaded from the gene 230 expression omnibus 16, 17, [40] [41] [42] [43] [44] [45] [46] (Table S1; The SU-DHL-2 cell line was obtained from ATCC. The RIVA (aka RI-1), HBL1, TMD8, U2932 and 263 OCI-Ly10 cell lines were obtained from DSMZ. The DNA copy number profile of DLBCL cell lines 264 were derived from previously reported SNP6.0 data 54 or targeted next generation sequencing, as 265 described above. Cell of origin subtype was determined according to previous descriptions 8 . 266 U2932, RIVA, TMD8, HBL1, and SUDHL2 were maintained in RPMI-1640 media with 10% FBS 267 and 1% penicillin/streptomycin. OCI-LY1, OCI-LY7 and OCI-LY10 were maintained in IMDM 268 supplemented with 20% human serum and 1% penicillin/streptomycin. Cell lines were regularly 269 tested for mycoplasma, and identity confirmation by Short Tandem Repeat at core facility of MD Anderson Cancer Center. Tetracyline-inducible expression of TCF4 was performed in the TMD8, 271 HBL1, and SUDHL2 cell lines. Detailed methodology can be found in the supplementary methods. between TMD8 and SUDHL2, and peaks corresponding to genes with differential expression 301 between ABC-like DLBCL tumors with or without TCF4 DNA copy number gain. Peaks within 302 2kbp of the transcription start site were defined as 'promoter' peaks, those outside of the promoter 303 region but within the coding region of the gene were defined as 'intragenic' peaks, and those outside of these regions but within 50kbp of the transcription start site were defined as distant 305 'enhancer' peaks. For visualization, files were converted to wiggle format and viewed using the 306 No. A301-985A) following the protocol as described above for TCF4. Chromatin DNA was also 315 purified from the input samples. The purified DNA was used to perform quantitative PCR using 316 SYBR Green/ROX qPCR Master Mix (Applied Biosystem; 4309155). Percentage of input was 317 quantified from the adjusted input Ct values and further used to determine ∆Ct values for BRD4 318 or IgG ChIP. Primers used for ChIP-PCR have been listed in Table S10 . 
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Figure 2: The TCF4 gene is the most significant target of 18q DNA copy number gains. A) 620
A schematic of 18q DNA copy number gains is shown, with each line representing a single tumor 621 and deeper shades of red indicating higher DNA copy number. The GISTIC q-value is shown at 622 the top of the diagram and the two significant peaks are highlighted with arrows. The most 623 statistically significant peak harbors the TCF4 gene, while the less significant peak harbors the 624 
